Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,042Revenue $M2.6Net Margin (%)--Altman Z-Score43.5
Enterprise Value $M789EPS $-0.7Operating Margin %--Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.7Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %-33.0Quick Ratio19.6Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-3.2Current Ratio19.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-45.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M118ROIC % (ttm)-616.6Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNFirst Eagle Investment 2014-03-31 Sold Out -0.01%$3.08 - $4.2
($3.5)
$ 8.58145%Sold Out0
ACHNFirst Eagle Investment 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 8.58196%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 8.5817%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 8.58-10%Reduce 50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 8.5840%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 8.5835%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-46.38 view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-42.8 view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.2-15.88 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-23.19 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-24 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$20356.3-99.96 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-11Sell1,704,362$12.45-31.08 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-02Sell835,293$11.63-26.23 view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-08-27Sell2,711,352$11.33-24.27 view
Truitt JosephEVP, Chief Commercial Officer 2014-08-25Sell25,000$10.82-20.7 view

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 

More From Other Websites
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 01 2015
Edited Transcript of ACHN presentation 23-Jun-15 1:00pm GMT Jun 24 2015
Achillion to Present at the JMP Securities Life Sciences Conference 2015 Jun 18 2015
Achillion to Present at the JMP Securities Life Sciences Conference 2015 Jun 18 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Jun 08 2015
Billionaire Steve Cohen Bullish Again (And Now More Than Ever) On Achillion Pharmaceuticals, Inc.... May 31 2015
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 27 2015
The Zacks Analyst Blog Highlights: Eleven Biotherapeutics, bluebird, Agios, Acceleron and Achillion... May 21 2015
Biotech Stock Roundup: Eleven Bio Slumps on Eye Drug Data, Achillion Signs Deal with J&J - Analyst... May 20 2015
Will the J&J Deal With Achillion Transform the Hep C Market? May 20 2015
Johnson & Johnson's big plans May 20 2015
Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat... May 20 2015
Achillion Pharma downgraded by JMP Securities May 20 2015
Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen May 19 2015
Achillion Enters Into Worldwide Collaboration for Hepatitis C With Janssen May 19 2015
Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 15.3% - Tale of the Tape May 19 2015
Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest May 19 2015
ACHILLION PHARMACEUTICALS INC Financials May 15 2015
10-Q for Achillion Pharmaceuticals, Inc. May 10 2015
Achillion Reports First Quarter 2015 Financial Results May 07 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK